NANCY K. BRYAN is an established leader with more than 25 years of experience in the life sciences industry. She has served on executive leadership teams and played key roles in companies’ successes, including marketing, sales, business development, financing and communications. Bryan is the current President and CEO of BioFlorida Inc., an association supporting the advancement of life sciences in Florida. Prior to joining BioFlorida as its President and CEO in 2013, Bryan began her career with major pharmaceutical companies including Merck, GlaxoSmithKline and Bayer Pharmaceuticals. She then went on to serve in a number of executive leadership positions in specialty pharmaceuticals and smaller, start-up biotech companies, including Indevus Pharmaceuticals and NPS Pharmaceuticals. Throughout her career, Bryan helped develop, launch and commercialize many products including blockbusters (Zantac, Levitra), major biologics (Tysabri) and orphan drugs for rare diseases (Valstar for bladder cancer, Supprelin LA for central precocious puberty), and helped establish franchises in a wide variety of therapeutic areas, including Oncology, Anti-infectives, GI and Autoimmune (MS, CD). She has established a successful track record with introducing strategic and tactical solutions to develop global markets as well as launch, grow and turn around established and underperforming drugs, resulting in greater revenue, market share, profitability and stockholder value. Additionally, Bryan has been recognized for outstanding leadership experience in the specialty, biologics and primary care markets, establishing franchises in a wide variety of therapeutic areas, including Oncology, GI, Urology, Endocrinology, Cardiology, Vaccines, Anti-infectives and Autoimmune (IBD, MS, RA).
Bryan holds a BA in Economics from the University of Virginia and an MBA from Columbia University, and her academic honors include Phi Beta Kappa and Beta Gamma Sigma.
What is Nancy Bryan's net worth?
The estimated net worth of Nancy Bryan is at least $564.48 as of March 21st, 2024. Ms. Bryan owns 384 shares of AIM ImmunoTech stock worth more than $564 as of December 4th. This net worth approximation does not reflect any other assets that Ms. Bryan may own. Learn More about Nancy Bryan's net worth.
How do I contact Nancy Bryan?
Has Nancy Bryan been buying or selling shares of AIM ImmunoTech?
Nancy Bryan has not been actively trading shares of AIM ImmunoTech within the last three months. Most recently, on Thursday, March 21st, Nancy Bryan bought 384 shares of AIM ImmunoTech stock. The stock was acquired at an average cost of $39.00 per share, with a total value of $14,976.00. Following the completion of the transaction, the director now directly owns 384 shares of the company's stock, valued at $14,976. Learn More on Nancy Bryan's trading history.
Who are AIM ImmunoTech's active insiders?
Are insiders buying or selling shares of AIM ImmunoTech?
In the last twelve months, AIM ImmunoTech insiders bought shares 4 times. They purchased a total of 1,475 shares worth more than $17,268.00. The most recent insider tranaction occured on April, 4th when COO Peter W Rodino III bought 5 shares worth more than $45.00. Insiders at AIM ImmunoTech own 0.0% of the company.
Learn More about insider trades at AIM ImmunoTech. Information on this page was last updated on 4/4/2025.